Business Context and Reporting Period
Deep Medicine Acquisition Corp., a special purpose acquisition company (SPAC) associated with the proposed Trugolf Holdings transaction, filed this Form 8-K on July 13, 2023, with the report signed on July 14, 2023. The filing concerns an extension of the deadline to complete its initial business combination, non-redemption agreements, and stockholder redemptions.
Key Financial and Capital Metrics
| Metric | Reported amount |
|---|---|
| Public shares redeemed | 255,446 |
| Funds expected to be withdrawn from trust | Approximately $2,914,230 |
| Approximate redemption value per share | $11.41 |
| Public shares outstanding after redemptions | 574,764 |
| Shares covered by non-redemption agreements | Up to 434,548 public shares |
| Sponsor shares potentially transferred under those agreements | Up to 156,298 shares |
The filing does not provide revenue, operating profit, margins, cash flow, debt, or liquidity figures beyond the trust-account redemption information.
Material Changes Versus the Prior Period
- The deadline to complete the initial business combination was extended from July 29, 2023 to January 29, 2024, or an earlier date determined by the board.
- Four unaffiliated third parties entered into non-redemption agreements covering up to 434,548 public shares.
- Holders of 255,446 public shares elected to redeem, reducing public shares outstanding to 574,764 and reducing the trust account by approximately $2.9 million.
Guidance, Outlook, Risks, and Unusual Items
Stockholders approved the extension amendment proposal by 3,947,761 votes for and 206,576 votes against, with no abstentions or broker non-votes. The extension provides additional time to complete the initial business combination but does not ensure that a transaction will close.
The redemptions reduce the cash available in the trust account and the number of remaining public shares. The non-redemption agreements may mitigate the reduction in public shares, but the filing states that the share transfers are subject to consummation of the initial business combination. No operating guidance or management forecast was provided.
Investor Verification Checklist
- Verify the final trust-account balance after the $2,914,230 redemption payment.
- Confirm the terms and beneficiaries of the four non-redemption agreements.
- Confirm whether the initial business combination with the proposed target is completed by January 29, 2024 or an earlier board-designated date.
- Review the filed second amendment to the Second Amended and Restated Certificate of Incorporation.
- Verify the final post-redemption ownership, dilution, and sponsor share-transfer effects.